Skip to main content
Fig. 1 | Molecular Brain

Fig. 1

From: The high-affinity IgG receptor FcγRI modulates peripheral nerve injury-induced neuropathic pain in rats

Fig. 1

The high-affinity IgG receptor FcγRI modulates peripheral nerve injury-induced neuropathic pain. Modulation of FcγRI by using the anti-FcγRI antibodyattenuated peripheral nerve injury-induced neuropathic pain (a, b), and related to changes in expression of inflammatory mediators (c-e) in rats, related to inflammatory responses in cells (f-h). a The mechanical allodynia of neuropathic pain was induced by peripheral nerve injury, and significantly reversed by the anti-FcγRI antibody in rats. Each value represented the paw withdrawal threshold by von Frey test (n = 16). b The thermal allodynia was induced by peripheral nerve injury in rats, and remarkably attenuated by the anti-FcγRI antibody. Each value represented paw withdrawal thermal latency by heat tests (n = 16). c-e The expression of neuropeptide substance P (c) and cytokines TNF-α (d) and C3 (e) in the spinal cords were determined with real-time PCR (n = 3). f-i Modulation of FcγRI through anti-FcγRI antibody and IgG immune complex and effects on inflammatory responses in PC12 cells. The expression of FcγRI protein was determined and quantified by Western blotting analysis (n = 3). The protein levels were quantified by ImageJ software (f). Quantification of levels of TNF-α (g) and substance P (h) in PC12 cells incubated with IgG immune complex and/or the anti-FcγRI antibody using ELISA (n = 5). Data was presented as means ± S.E.M. *P < 0.05, compared to the C group; #P < 0.05, compared with the IC group; $$P < 0.01, compared with the S group; &P < 0.05, &&P < 0.01, &&&P < 0.001, compared with the NP group. Abbreviations: C, the control group (cells without IgG immune complex); IC, cells with IgG immune complex; IF, cells with IgG immune complex and the anti-FcγRI antibody; F, cells with the anti-FcγRI antibody; S, the sham group; NP, neuropathic pain model with pain behaviors; NF, neuropathic pain model with the anti-FcγRI antibody

Back to article page